79.93
price down icon0.15%   -0.12
after-market アフターアワーズ: 79.75 -0.18 -0.23%
loading
前日終値:
$80.05
開ける:
$80.055
24時間の取引高:
4.86M
Relative Volume:
1.09
時価総額:
$247.89B
収益:
$56.53B
当期純損益:
$8.32B
株価収益率:
29.83
EPS:
2.6798
ネットキャッシュフロー:
$8.49B
1週間 パフォーマンス:
-0.73%
1か月 パフォーマンス:
+10.01%
6か月 パフォーマンス:
+5.66%
1年 パフォーマンス:
-8.35%
1日の値動き範囲:
Value
$79.47
$80.26
1週間の範囲:
Value
$79.38
$81.56
52週間の値動き範囲:
Value
$61.24
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
名前
Astrazeneca PLC
Name
セクター
Healthcare (1146)
Name
電話
44 20 3749 5000
Name
住所
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
職員
61,100
Name
Twitter
@AstraZeneca
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
AZN's Discussions on Twitter

AZN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
79.93 246.98B 56.53B 8.32B 8.49B 2.6798

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 開始されました Exane BNP Paribas Outperform
2025-02-13 アップグレード UBS Neutral → Buy
2025-02-12 開始されました Morgan Stanley Overweight
2024-11-20 アップグレード UBS Sell → Neutral
2024-11-06 アップグレード Deutsche Bank Sell → Hold
2024-09-13 ダウングレード Deutsche Bank Hold → Sell
2024-05-30 開始されました Goldman Buy
2024-04-16 アップグレード Deutsche Bank Sell → Hold
2024-02-08 ダウングレード Deutsche Bank Hold → Sell
2024-01-23 開始されました Morgan Stanley Overweight
2024-01-16 再開されました UBS Sell
2024-01-03 ダウングレード Jefferies Buy → Hold
2023-12-18 開始されました HSBC Securities Buy
2023-09-25 アップグレード Jefferies Hold → Buy
2023-07-14 開始されました HSBC Securities Buy
2023-07-12 アップグレード UBS Neutral → Buy
2023-07-05 ダウングレード Deutsche Bank Buy → Hold
2023-04-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-01-05 開始されました BMO Capital Markets Outperform
2022-09-15 ダウングレード Credit Suisse Outperform → Neutral
2022-09-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-08-29 アップグレード Argus Hold → Buy
2022-06-14 ダウングレード UBS Buy → Neutral
2022-02-11 アップグレード DZ Bank Sell → Hold
2021-12-07 ダウングレード Jefferies Buy → Hold
2021-08-12 再開されました JP Morgan Overweight
2021-04-12 ダウングレード Argus Buy → Hold
2021-03-16 アップグレード Jefferies Hold → Buy
2021-02-25 アップグレード UBS Neutral → Buy
2021-01-15 開始されました Deutsche Bank Buy
2020-12-07 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-11-30 アップグレード UBS Sell → Neutral
2020-11-11 アップグレード HSBC Securities Reduce → Hold
2020-09-29 開始されました Berenberg Buy
2019-11-22 開始されました SVB Leerink Outperform
2019-10-25 アップグレード Liberum Hold → Buy
2019-04-02 ダウングレード UBS Neutral → Sell
2019-02-05 開始されました Exane BNP Paribas Outperform
2019-01-25 アップグレード Shore Capital Hold → Buy
2018-12-11 再開されました Jefferies Hold
2018-10-09 開始されました Guggenheim Buy
2018-08-16 ダウングレード Jefferies Buy → Hold
2018-03-19 アップグレード Jefferies Hold → Buy
2018-02-06 繰り返されました Leerink Partners Mkt Perform
2018-02-05 繰り返されました Bernstein Outperform
2018-01-18 繰り返されました Leerink Partners Mkt Perform
2017-12-29 アップグレード JP Morgan Neutral → Overweight
2017-10-16 アップグレード Credit Suisse Neutral → Outperform
2017-09-25 アップグレード Exane BNP Paribas Neutral → Outperform
2017-09-22 アップグレード Bernstein Mkt Perform → Outperform
すべてを表示

Astrazeneca PLC (AZN) 最新ニュース

pulisher
03:50 AM

University of Michigan Suit Targets AstraZeneca FluMist Profits - Bloomberg Law News

03:50 AM
pulisher
01:25 AM

AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO [Video] - AOL.com

01:25 AM
pulisher
01:00 AM

Global Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.

01:00 AM
pulisher
12:39 PM

AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks

12:39 PM
pulisher
09:26 AM

Published on: 2025-08-27 08:26:33 - Newser

09:26 AM
pulisher
08:30 AM

Va. backs big pharma deals for AstraZeneca in Albemarle, Eli Lilly in Goochland - Richmond Times-Dispatch

08:30 AM
pulisher
02:01 AM

Evaluating AstraZeneca PLC Depositary Receipt with trendline analysis2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser

02:01 AM
pulisher
12:31 PM

Tools to monitor AstraZeneca PLC Depositary Receipt recovery probabilityWeekly Market Report & Weekly Top Gainers Alerts - Newser

12:31 PM
pulisher
12:00 PM

AstraZeneca bounces back from scandal in China - Financial Times

12:00 PM
pulisher
Aug 26, 2025

AstraZeneca PLC Depositary Receipt Recovery Hinges on Volume Breakout getLinesFromResByArray error: size == 0 - 더경남뉴스

Aug 26, 2025
pulisher
Aug 26, 2025

AstraZeneca Sees Increase in Voting Rights by The Capital Group - TipRanks

Aug 26, 2025
pulisher
Aug 26, 2025

What candlestick patterns are forming on AstraZeneca PLC Depositary Receipt2025 Market Outlook & Daily Stock Trend Watchlist - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Published on: 2025-08-26 09:01:55 - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Is a relief rally coming for AstraZeneca PLC Depositary Receipt holdersWeekly Profit Analysis & Reliable Volume Spike Trade Alerts - Newser

Aug 26, 2025
pulisher
Aug 26, 2025

Multi asset correlation models including AstraZeneca PLC Depositary Receipt2025 Macro Impact & Breakout Confirmation Trade Signals - Newser

Aug 26, 2025
pulisher
Aug 25, 2025

AstraZeneca PLC ADR falls Monday, underperforms market - MarketWatch

Aug 25, 2025
pulisher
Aug 25, 2025

AstraZeneca’s New NSCLC Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 25, 2025
pulisher
Aug 25, 2025

Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China - Pharmaceutical Technology

Aug 25, 2025
pulisher
Aug 24, 2025

Is it time to cut losses on AstraZeneca PLC Depositary ReceiptPrice Action & Stock Market Timing Techniques - Newser

Aug 24, 2025
pulisher
Aug 24, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Aug 24, 2025
pulisher
Aug 23, 2025

AstraZeneca’s New Asthma Study: Potential Market Impact - TipRanks

Aug 23, 2025
pulisher
Aug 22, 2025

AstraZeneca’s New Study on Tezepelumab for CRSwNP: A Potential Game-Changer - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

Amgen and AstraZeneca Launch Promising Phase 3 Lung Cancer Study - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s Innovative Lung Cancer Screening Study: A Game Changer for Early Detection - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s ARISE Study: Real-World Insights on Acalabrutinib for CLL - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s DESTINY-Endometrial01 Study: A New Horizon in Endometrial Cancer Treatment - TipRanks

Aug 22, 2025
pulisher
Aug 22, 2025

AstraZeneca’s AZD9829 Study: A New Hope in Hematological Cancer Treatment - TipRanks

Aug 22, 2025
pulisher
Aug 21, 2025

AstraZeneca’s GEMINI-PeriOp GC Study: A New Frontier in Gastroesophageal Cancer Treatment - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s CHRONICLES COPD Study: A New Horizon in COPD Treatment - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s New CAR T-Cell Therapy Study: A Potential Game-Changer for Multiple Myeloma - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s New Study on Crohn’s Disease Treatment: Key Insights for Investors - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

AstraZeneca’s Phase III COPD Study: A Potential Game-Changer in Respiratory Treatment - TipRanks

Aug 21, 2025
pulisher
Aug 21, 2025

Earnings call transcript: AstraZeneca’s Q2 2025 earnings exceed expectations - Investing.com

Aug 21, 2025
pulisher
Aug 20, 2025

AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Benralizumab Study Completes: A Potential Game-Changer for COPD Treatment - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Phase 3 Study on Advanced Biliary Tract Cancer: A Potential Game-Changer? - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Atuliflapon Study: A New Hope for Uncontrolled Asthma - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Saruparib Study: A New Frontier in Cancer Treatment? - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? - TipRanks

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca advances Wednesday, outperforms market - MarketWatch

Aug 20, 2025
pulisher
Aug 20, 2025

AstraZeneca’s New Asthma Treatment Study: What Investors Should Know - TipRanks

Aug 20, 2025
pulisher
Aug 19, 2025

Fitch Upgrades AstraZeneca on Profit Growth; Ratings Withdrawn for Commercial Reasons - MarketScreener

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s Benralizumab Study: A Step Forward in COPD Treatment - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

Risk adjusted return profile for AstraZeneca PLC Depositary Receipt analyzed2025 Risk Factors & Intraday High Probability Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s Promising Asthma Treatment: A Closer Look at the Atuliflapon Study - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s Phase I Study on Saruparib: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 19, 2025
pulisher
Aug 19, 2025

AstraZeneca’s New Study on Advanced Biliary Tract Cancer: A Potential Game Changer? - TipRanks

Aug 19, 2025
pulisher
Aug 18, 2025

AstraZeneca Receives Chinese Approval to Acquire FibroGen China - MarketScreener

Aug 18, 2025
pulisher
Aug 18, 2025

AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Market Game-Changer - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

AstraZeneca CFO Aradhana Sarin sells 9,563 shares in London transaction - Investing.com

Aug 18, 2025
pulisher
Aug 17, 2025

AstraZeneca’s New Study on T-DXd Offers Hope for HER2-Positive Tumor Patients - MSN

Aug 17, 2025

Astrazeneca PLC (AZN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
大文字化:     |  ボリューム (24 時間):